← Back

Slovenia JAZMP · Slovenia · 3 Sep 2026 · Safety alert & recall

Rybelsus (oral semaglutide): Direct Healthcare Professional Communication on medication error risk

Original title: Rybelsus (peroralni semaglutid): obvestilo za zdravstvene delavce

Read at Slovenia JAZMP ↗
Pharmaceuticals
AI-generated summary

The Slovenian medicines agency JAZMP published a Direct Healthcare Professional Communication warning of medication error risks with Rybelsus (oral semaglutide) due to introduction of a new formulation with increased bioavailability, available on the Slovenian market in the first half of September.

From Slovenia JAZMP

Zdravstvene delavce obveščamo, da je na spletni strani JAZMP objavljeno neposredno obvestilo (angl. DHPC – Direct Healthcare Professional Communication) o tveganju za napake pri uporabi zdravila zaradi uvedbe nove formulacije zdravila Rybelsus s povečano biološko uporabnostjo, ki bo na slovenskem trgu na voljo v prvi polovici septembra.

Obvestilo je dostopno na naslednji povezavi.

Excerpt from the official page. The original is authoritative.